Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

De novo Protein Sequencing of Antibodies for Identification of Neutralizing Antibodies in Human Plasma Post SARS-CoV-2 Vaccination - Benchmark Study

ABSTRACT: This dataset submission includes the raw files used to sequence a mix of 5 human monoclonal antibodies as a benchmark proof-of-concept study for the manuscript "de novo Protein Sequencing of Antibodies for Identification of Neutralizing Antibodies in Human Plasma Post SARS-CoV-2 Vaccination". Refer to the attached metafile for detailed descriptions of the experiments. Briefly, bottom-up data was generated by performing in-solution digestions on the monoclonal antibodies on their own and after mixing to generate a pseudo-polyclonal mix. Separation was performed using native gel and non-reducing SDS-PAGE (NRT), followed by in-gel digestion for heavy-light chain pairing. Lastly, C-terminal modification and EThcD fragmentation of in-solution digests allowed for I/L determination.

INSTRUMENT(S): Orbitrap Eclipse, Orbitrap Fusion Lumos, Orbitrap Exploris 240

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Thierry Le Bihan

PROVIDER: MSV000094953 | MassIVE | Thu Jun 06 19:21:00 BST 2024

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

de novo Protein Sequencing of Antibodies for Identification of Neutralizing Antibodies in Human Plasma Post SARS-CoV-2 Vaccination

Project description:We are submitting raw data files used for de novo sequencing of human polyclonal antibodies targeting receptor binding domain (RBD) from covid-19 virus to generate recombinantly produced monoclonal antibodies capable of neutralizing RBD. The raw files submitted are described in the metafile included, but in brief, they are categorized as data generation (i.e., bottom-up in-solution enzymatic digestion), native gel separation followed by digestion, non-reducing room temperature (NRT) gel separation followed by digestion, middle-down, non-reducing, and isobaric resolution.

2023-11-24 | MSV000093480 | MassIVE

Prediction of broadly neutralizing antibodies

Project description:Prediction of broadly neutralizing antibodies

| PRJNA952996 | ENA

Prediction of broadly neutralizing antibodies [10X]

Project description:Prediction of broadly neutralizing antibodies [10X]

| PRJNA952157 | ENA

Prediction of broadly neutralizing antibodies [Singleron]

Project description:Prediction of broadly neutralizing antibodies [Singleron]

| PRJNA952999 | ENA

Prediction of broadly neutralizing antibodies [Singleron]

Project description:We generated the humoral immune repertoire of circulating memory B cells from healthy and HIV infected immune donors. These repertoires were used to predict specific HIV antibodies directed against gp120/gp41.

2024-06-04 | GSE229122 | GEO

Prediction of broadly neutralizing antibodies [10X]

2024-06-04 | GSE228912 | GEO

Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through NK cell mediated killing

Project description:A series of monoclonal antibodies (mAbs) against human immune deficiency virus (HIV) were prepared utilizing different variable regions targeting HIV epitopes in combination with glycoengineering to produce mAbs with low Fc fucosylation. This dataset pertains to the Fc N-glycosylation analysis of these mAbs.

2024-07-30 | PXD053363 | Pride

Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies

Project description:Many human monoclonal antibodies that neutralize multiple clades of HIV-1 are polyreactive and bind avidly to mammalian autoantigens. Indeed, the generation of neutralizing antibodies to the 2F5 and 4E10 epitopes of HIV-1 gp41 in man may be proscribed by immune tolerance since mice expressing the VH and VL regions of 2F5 have a block in B-cell development characteristic of central tolerance. This developmental blockade implies the presence of tolerizing autoantigens that are mimicked by the membrane-proximal external region of HIV-1 gp41. Here we identify human kynureninase (KYNU) and splicing factor 3b subunit 3 (SF3B3) as the primary conserved, vertebrate self-antigens recognized by the 2F5 and 4E10 antibodies, respectively. 2F5 binds the H4 domain of KYNU which contains the complete 2F5 linear epitope (ELDKWA). 4E10 recognizes a conformational epitope of SF3B3 that is strongly dependent on hydrophobic interactions. Opossums carry a rare KYNU H4 domain that abolishes 2F5 binding, but retain all SF3B3 4E10 epitopes. Immunization of opossums with HIV-1 gp140 induced extraordinary titers of serum antibody to the 2F5 ELDKWA epitope but little or nothing to the 4E10 determinant. Identification of structural motif shared by vertebrates and HIV-1 provides direct evidence that immunological tolerance can impair humoral responses to HIV-1.

2012-12-03 | GSE42673 | GEO

Neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic activity

Project description:SARS-CoV-2 has spread globally and caused the COVID-19 pandemic. Although passively delivered neutralizing antibodies against SARS-CoV-2 are in clinical trials, their mechanism of action in vivo is incompletely understood. Here, we define correlates of protection of neutralizing human monoclonal antibodies (mAbs) in SARS-CoV-2-infected mice. Whereas Fc effector functions are fully dispensable when mAbs are administered as prophylaxis, they are required for optimal protection as therapy. When given after infection, intact but not LALA-PG loss of Fc effector function variant mAbs reduce SARS-CoV-2 burden and lung disease in mice and hamsters. Fc engagement of neutralizing antibodies mitigates inflammation and improves respiratory mechanics, and transcriptional profiling suggests these phenotypes are associated with diminished innate immune signaling and enhanced tissue repair. Immune cell depletions establish that neutralizing mAbs require monocytes for therapeutic efficacy. Our study demonstrates that therapeutic neutralizing mAbs require Fc effector functions to reduce SARS-CoV-2 infection and modulate protective immune responses.

2021-03-01 | GSE161615 | GEO

Prediction of broadly neutralizing antibodies [BD Rhapsody]

2024-06-04 | GSE229121 | GEO